ETX-19477

DRUG2 trials

Sponsors

858 Therapeutics Inc., 858 Therapeutics, Inc.

Conditions

Advanced or Metastatic Solid TumorsBRCA MutationBRCA1 MutationBRCA2 MutationBreast CancerCastrate Resistant Prostate CancerColorectal CancerER+ Breast Cancer

Phase 1

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

RecruitingNCT06395519

858 Therapeutics, Inc.Advanced or Metastatic Solid Tumors, BRCA1 Mutation, BRCA2 Mutation +10

Start: 2024-05-13End: 2026-12-01Target: 120Updated: 2026-03-27

PHASE 1/2 STUDY OF PARG INHIBITOR ETX-19477 IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES

Not yet recruitingCTIS2024-518326-32-00

858 Therapeutics Inc.Patients with advanced solid malignancies that have progressed following standard therapy

Target: 28Updated: 2025-04-02

Related Papers

First-in-human phase 1/2 study of ETX-19477, an oral, potent, and selective PARG inhibitor, in patients with advanced solid tumors (ERADIC8).

Journal of Clinical Oncology2026-05-27